for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Conatus Pharmaceuticals Inc

CNAT.OQ

Latest Trade

0.37USD

Change

-0.01(-3.79%)

Volume

20,297

Today's Range

0.36

 - 

0.38

52 Week Range

0.25

 - 

6.73

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
0.38
Open
0.38
Volume
20,297
3M AVG Volume
26.21
Today's High
0.38
Today's Low
0.36
52 Week High
6.73
52 Week Low
0.25
Shares Out (MIL)
33.17
Market Cap (MIL)
12.18
Forward P/E
-0.99
Dividend (Yield %)
--

Latest Developments

More

Conatus Pharmaceuticals Reports Q2 2019 Results

Conatus To Explore Strategic Alternatives, To Reduce Staff By About 40%

Conatus Says Top-Line Results From Encore-LF Clinical Trial Of Emricasan Did Not Meet Primary Endpoint

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Conatus Pharmaceuticals Inc

Conatus Pharmaceuticals Inc. is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease. Emricasan has the potential to interrupt the progression of liver disease and provide treatment options in multiple areas of liver disease. Emricasan is designed to slow or halt the progression of chronic liver disease caused by fibrosis and cirrhosis. Emricasan works by inhibiting caspases, which are a family of related enzymes that plays as modulators of critical cellular functions, including functions that result in apoptosis and inflammation.

Industry

Biotechnology & Drugs

Contact Info

16745 W Bernardo Dr Ste 200

+1.858.3762600

https://www.conatuspharma.com/

Executive Leadership

David F. Hale

Independent Chairman of the Board

Steven J. Mento

President, Chief Executive Officer, Director

Keith W. Marshall

Chief Financial Officer, Principal Financial Officer, Chief Operating Officer, Executive Vice President

Alfred P. Spada

Executive Vice President - Research & Development, Chief Scientific Officer

David T. Hagerty

Executive Vice President, Clinical Development

Key Stats

3.00 mean rating - 1 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-1.310

2017

-0.610

2018

-0.590

2019(E)

-0.370
Price To Earnings (TTM)
--
Price To Sales (TTM)
0.37
Price To Book (MRQ)
0.51
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-43.72
Return on Equity (TTM)
-26.97

Latest News

Conatus Pharma to explore options as liver disease drug fails trial

Conatus Pharmaceuticals Inc said on Monday it plans to explore options and implement a restructuring plan after its liver disease drug failed in a mid-stage trial.

BRIEF-Conatus Says Top-Line Results From Encore-LF Clinical Trial Of Emricasan Did Not Meet Primary Endpoint

* CONATUS ANNOUNCES RESULTS FROM ENCORE-LF AND ENCORE-PH PHASE 2B CLINICAL TRIALS IN NASH CIRRHOSIS

Conatus Pharma to explore options, liver disease drug fails trial

Conatus Pharmaceuticals Inc said on Monday it will cut staff by about 40% as part of a restructuring plan and explore options.

BRIEF-Conatus Completes Enrollment In Phase 2B Clinical Trial Of Emricasan In Patients With Decompensated Nash Cirrhosis

* CONATUS ANNOUNCES COMPLETION OF ENROLLMENT IN ENCORE-LF PHASE 2B CLINICAL TRIAL OF EMRICASAN IN PATIENTS WITH DECOMPENSATED NASH CIRRHOSIS

BRIEF-Conatus Pharmaceuticals Q1 Revenue $9.7 Million

* CONATUS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROGRAM UPDATES

BRIEF-Conatus Pharmaceuticals Announces Top-Line Results From Phase 2B POLT-HCV SVR Clinical Trial

* CONATUS PHARMACEUTICALS ANNOUNCES TOP-LINE RESULTS FROM PHASE 2B POLT-HCV SVR CLINICAL TRIAL

BRIEF-Conatus Pharmaceuticals Q4 Revenue $8.8 Million

* CONATUS PHARMACEUTICALS REPORTS 2017 FINANCIAL RESULTS AND PROGRAM UPDATES

BRIEF-Conatus Pharmaceuticals reports Q3 revenue of $9.6 million

* Conatus Pharmaceuticals Inc reports third quarter 2017 financial results and program updates

BRIEF-EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC

* EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC

BRIEF-Conatus Pharmaceuticals files for mixed shelf of upto $100 mln

* Conatus Pharmaceuticals Inc files for mixed shelf of upto $100 million - SEC filing Source text: (http://bit.ly/2x8wope) Further company coverage:

BRIEF-Conatus announces completion of enrollment

* Conatus announces completion of enrollment in encore-NF phase 2B clinical trial of emricasan in patients with NASH fibrosis Source text for Eikon: Further company coverage:

BRIEF-Conatus announces effectiveness of exclusive license with Novartis

* Conatus Pharmaceuticals - exclusive license with Novartis for global development and commercialization of emricasan has become effective under terms

BRIEF-FDA grants Conatus orphan drug designation for idn-7314 for the treatment of PSC

* FDA grants conatus orphan drug designation for idn-7314 for the treatment of PSC Source text for Eikon: Further company coverage:

BRIEF-Conatus prices offering of 5.20 mln shares at $5.50/shr

* Conatus announces pricing of public offering of common stock

BRIEF-Conatus Pharmaceuticals Q1 revenue $7.0 million

* Conatus Pharmaceuticals reports first quarter 2017 financial results and program updates

Novartis exercises option with Conatus for NASH product

Novartis is exercising its option with Conatus Pharmaceuticals for an exclusive license for the global development and commercialization of emricasan for treating liver disease NASH, the Swiss drugmaker said.

BRIEF-Conatus Pharmaceuticals says appointed Steven Mento as acting principal financial officer on March 16

* Conatus Pharmaceuticals Inc - on March 16, board appointed Steven Mento as company's acting principal financial officer Source text: (http://bit.ly/2mN9zSd) Further company coverage:

BRIEF-Conatus Pharma qtrly loss per share $0.35

* Conatus pharmaceuticals reports 2016 financial results and program updates

BRIEF-Conatus Pharmaceuticals says cfo Charles Cashion resigned

* On February 16, 2017, Charles J. Cashion tendered his resignation as chief financial officer Source text- http://bit.ly/2lfEBmE Further company coverage:

BRIEF-Conatus Pharmaceuticals issued a convertible promissory note of $15 mln to Novartis Pharma AG pursuant to investment agreement entered in Dec 2016

* Conatus Pharmaceuticals - On Feb 15, co issued a convertible promissory note of $15 million to Novartis Pharma AG pursuant to investment agreement entered in Dec 2016 Source text: [http://bit.ly/2lpeTOz] Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up